Editorial

Dipyrone (Metamizole) Use in the United States: A Lethal Tango?

Authors: Jonathan Moorman, MD, PHD

Abstract

The nonsteroidal agent dipyrone (metamizole) was banned by the United States Federal Drug Administration (FDA) in the late 1970s after it was associated with myelotoxicity. This toxicity and, specifically, the development of agranulocytosis remain a topic of discussion within the medical literature. Less debatable, but perhaps more surprising, is the fact that this drug is still commonly seen in the United States despite the FDA ban. As described by Garcia et al,1 dipyrone was found in 28% of surveyed Latino households in Miami. The drug is generally obtained over the counter in Latin America and is being used by Latinos for treatment of pain and/or fever.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Garcia S, Canoniero M, Lopez G, et al. Metamizole use among Hispanics living in the United States: report of a survey conducted in a primary care setting in Miami. Southern Med J 2006;99:924–926.
 
2. Ibanez L, Vidal X, Ballarin E, et al. Population-based drug-induced agranulocytosis. Arch Intern Med2005;165:869–874.
 
3. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 2002;58:265–274.
 
4. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA1986;256:1749–1757.
 
5. Edwards JE, McQuay HJ. Dipyrone and agranulocytosis: what is the risk? Lancet 2002;360:1438.
 
6. Hamerschlak N, Maluf E, Pasquini R, et al. Incidence of aplastic anemia and agranulocytosis in Latin America–the LATIN study. Sao Paulo Med J 2005;123:101–104.
 
7. Vlahov V, Bacracheva N, Tontcheva D, et al. Genetic factors and risk of agranulocytosis from metamizol. Pharmacogenetics 1996;6:67–72.
 
8. Bensenor IM. Dipyrone and blood dyscrasia revisited: “non-evidence based medicine.” Sao Paulo Med J 2005;123:99–100.
 
9. Hamerschlak N, Cavalcanti AB. Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med J2005;123:247–249.